Aims REVEAL was the first randomized controlled trial to demonstrate that adding
cholesteryl ester transfer protein inhibitor therapy to intensive statin therapy reduced the risk …

Dyslipidemia is an independent risk factor of cardiovascular diseases (CVDs), which lead to
the high mortality, disability, and medical expenses in the worldwide. Based on the previous …

Statins are a class of widely prescribed drugs used to reduce low-density lipoprotein
cholesterol (LDL-C) and important to prevent cardiovascular diseases (CVD). Most statin …

Statin therapy has been shown to have a significant effect on lowering of low-density
lipoprotien cholesterol (LDL-C) levels. This subsequently results in cardiovascular (CV) …

Background Men using cholesterol-lowering statin medications have been found to have
lower risks of both advanced and fatal prostate cancer in multiple registry-based studies and …

Background Cardiovascular diseases are the leading cause of death in the United States,
yet a significant proportion of adults at high risk remain undetected by standard screening …

Background The effectiveness of lipid‐lowering therapy (LLT) is affected by both intensity
and adherence. This study evaluated the associations of LLT intensity, adherence, and the …

Atherosclerotic coronary artery disease has a complex pathogenesis which extends beyond
cholesterol intimal infiltration. It involves chronic inflammation of the coronary artery wall …

There is a strong and ever-growing body of evidence regarding the use of
pharmacogenomics to inform cardiovascular pharmacology. However, there is no common …

A growing body of work uses the paradigm of algorithmic fairness to frame the development
of techniques to anticipate and proactively mitigate the introduction or exacerbation of health …